IDH1 and central nervous system cancer: Of note, it remains unknown whether there is a difference in therapy-induced senescence across glioma subtypes, such as astrocytoma versus oligodendroglioma, low-grade versus high-grade, and across molecular characteristics (IDH-wild type versus mutant, MGMT methylated versus unmethylated).